Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer

por Dowsett, Mitch, Kilburn, Lucy, Rimawi, Mothaffar F., Osborne, C. Kent, Pogue-Geile, Katherine, Liu, Yuan, Jacobs, Samuel A., Finnigan, Melanie, Puhalla, Shannon, Dodson, Andrew, Martins, Vera, Cheang, Maggie, Perry, Sophie, Holcombe, Chris, Turner, Nick, Swift, Claire, Bliss, Judith M., Johnston, Stephen
Publicado 2022

MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice

por Paterson, Alexander H G, Lucas, Peter C, Anderson, Stewart J, Mamounas, Eleftherios P, Brufsky, Adam, Baez-Diaz, Luis, King, Karen M, Lad, Thomas, Robidoux, André, Finnigan, Melanie, Sampayo, Miguel, Tercero, Juan Carlos, Mairet, Joël Jean, Wolff, Antonio C, Fehrenbacher, Louis, Wolmark, Norman, Gomis, Roger R
Publicado 2021

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

por Perez, Edith A., Press, Michael F., Dueck, Amylou C., Jenkins, Robert B., Kim, Chungyeul, Chen, Beiyun, Villalobos, Ivonne, Paik, Soonmyung, Buyse, Marc, Wiktor, Anne E., Meyer, Reid, Finnigan, Melanie, Zujewski, JoAnne, Shing, Mona, Stern, Howard M., Lingle, Wilma L., Reinholz, Monica M., Slamon, Dennis J.
Publicado 2013